Literature DB >> 25809540

Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection.

T-C Tseng1, C-J Liu, C-L Chen, W-T Yang, H-C Yang, T-H Su, C-C Wang, S F-T Kuo, C-H Liu, P-J Chen, D-S Chen, J-H Kao.   

Abstract

BACKGROUND: Clearance of hepatitis B surface antigen (HBsAg) indicates clinical control of hepatitis B virus (HBV) infection. However, little is known about the impact of viral genomic variations on HBsAg loss.
METHODS: We explored the association between viral genomic factors and HBsAg loss in 2121HBeAg-negative patients. HBV pre-core stop codon (1896) and basal core promoter (BCP) (1762/1764) sequences were determined in patients with HBV DNA ≥200 IU/mL (N = 1693). The effect of HBV genotype on HBsAg loss was further validated in the whole cohort of 3445 HBsAg carriers.
RESULTS: The cumulative lifetime (age 28-75 years) incidence of HBsAg loss was 50.4% in 2121 HBeAg-negative patients. We found that genotype C, but not pre-core stop codon or BCP mutants, was associated with HBsAg loss. Compared to genotype B patients, genotype C patients had higher lifetime chance of HBsAg loss, with hazard ratio of 1.8 (95% confidence interval: 1.4-2.4). Multivariable analysis showed that male sex, elevated ALT levels, lower serum HBV DNA and HBsAg levels, and genotype C infection were associated with higher chance of HBsAg loss independently. We then performed sensitivity analysis, which re-included HBeAg-positive, cirrhotic and treatment-experienced patients, and confirmed the robustness of our results in 3445 HBsAg carriers.
CONCLUSION: Genotype C infection, compared to genotype B, is associated with a higher lifetime chance of HBsAg loss in Asian HBV carriers.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25809540     DOI: 10.1111/apt.13170

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  15 in total

1.  Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.

Authors:  Kali Zhou; Caitlin Contag; Evans Whitaker; Norah Terrault
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-01-22

2.  Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma.

Authors:  Tai-Chung Tseng; Chun-Jen Liu; Tung-Hung Su; Wan-Ting Yang; Chi-Ling Chen; Hung-Chih Yang; Chia-Chi Wang; Stephanie Fang-Tzu Kuo; Chen-Hua Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Am J Gastroenterol       Date:  2017-08-29       Impact factor: 10.864

3.  Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection.

Authors:  L H Nguyen; J Hoang; N H Nguyen; V D Vu; C Wang; H N Trinh; J Li; J Q Zhang; M H Nguyen
Journal:  Aliment Pharmacol Ther       Date:  2016-07-01       Impact factor: 8.171

Review 4.  Ideal Cure for Hepatitis B Infection: The Target is in Sight.

Authors:  Shrihari A Anikhindi; Ashish Kumar; Praveen Sharma; Vikas Singla; Naresh Bansal; Anil Arora
Journal:  J Clin Exp Hepatol       Date:  2017-11-07

Review 5.  Functional cure for chronic hepatitis B: accessibility, durability, and prognosis.

Authors:  Aixin Song; Xiao Lin; Xinyue Chen
Journal:  Virol J       Date:  2021-06-03       Impact factor: 4.099

6.  Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels.

Authors:  Jem Ma Ahn; Dong Hyun Sinn; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

7.  Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection.

Authors:  Wan-Ting Yang; Li-Wei Wu; Tai-Chung Tseng; Chi-Ling Chen; Hung-Chih Yang; Tung-Hung Su; Chia-Chi Wang; Stephanie Fang-Tzu Kuo; Chen-Hua Liu; Pei-Jer Chen; Ding-Shinn Chen; Chun-Jen Liu; Jia-Horng Kao
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

8.  Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.

Authors:  Chih-Chien Yao; Chao-Hung Hung; Tsung-Hui Hu; Sheng-Nan Lu; Jing-Hung Wang; Chung-Mo Lee; Chien-Hung Chen
Journal:  Sci Rep       Date:  2017-05-12       Impact factor: 4.379

Review 9.  Elimination of Hepatitis B: Is It a Mission Possible?

Authors:  Tai-Chung Tseng; Jia-Horng Kao
Journal:  BMC Med       Date:  2017-03-15       Impact factor: 8.775

10.  Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients.

Authors:  Yee Hui Yeo; Tai-Chung Tseng; Tetsuya Hosaka; Chris Cunningham; James Yan Yue Fung; Hsiu J Ho; Min-Sun Kwak; Huy N Trinh; Teerapat Ungtrakul; Ming-Lung Yu; Mariko Kobayashi; An K Le; Linda Henry; Jiayi Li; Jian Zhang; Tassanee Sriprayoon; Donghak Jeong; Tawesak Tanwandee; Ed Gane; Ramsey C Cheung; Chun-Ying Wu; Anna S Lok; Hyo-Suk Lee; Fumitaka Suzuki; Man-Fung Yuen; Jia-Horng Kao; Hwai-I Yang; Mindie H Nguyen
Journal:  Clin Transl Gastroenterol       Date:  2020-09       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.